Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Dow
Merck
Boehringer Ingelheim
Mallinckrodt

Last Updated: January 23, 2020

DrugPatentWatch Database Preview

NEUPOGEN Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Recent Clinical Trials for NEUPOGEN

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Rutgers, The State University of New JerseyEarly Phase 1
National Cancer Institute (NCI)Early Phase 1
Northwestern UniversityPhase 2

See all NEUPOGEN clinical trials

Recent Litigation for NEUPOGEN

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Village at Camp Bowie I, L.P.2010-08-02

See all NEUPOGEN litigation

Company Disclosures: US Patents for NEUPOGEN

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen NEUPOGEN filgrastim VIAL 103353 001 1991-02-20   Start Trial Kirin- Amgen Inc. (Thousand Oaks, CA) 2006-03-07 RX company
Amgen NEUPOGEN filgrastim VIAL 103353 001 1991-02-20   Start Trial Amgen Inc. (Thousand Oaks, CA) 2005-08-23 RX company
Amgen NEUPOGEN filgrastim VIAL 103353 001 1991-02-20   Start Trial Amgen Inc. (Thousand Oaks, CA) 2013-12-03 RX company
Amgen NEUPOGEN filgrastim VIAL 103353 001 1991-02-20   Start Trial Amgen Inc. (Thousand Oaks, CA) 2013-12-10 RX company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for NEUPOGEN

These patents were identified by searching patent claims

Supplementary Protection Certificates for NEUPOGEN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C20140027 00115 Estonia   Start Trial PRODUCT NAME: SILTUKSIMAB;REG NO/DATE: K(2014)3557 (LOPLIK) 27.05.2014
CA 2014 00047 Denmark   Start Trial PRODUCT NAME: SILTUXIMAB; REG. NO/DATE: EU/1/14/928/001-002 20140522
PA2010007 Lithuania   Start Trial PRODUCT NAME: ELTROMBOPAGUM OLAMINUM; REGISTRATION NO/DATE: EU/1/10/612/001, 2010 03 11 EU/1/10/612/002, 2010 03 11 EU/1/10/612/003, 2010 03 11 EU/1/10/612/004, 2010 03 11 EU/1/10/612/005, 2010 03 11 EU/1/10/612/006 20100311
C20100006 00032 Estonia   Start Trial PRODUCT NAME: REVOLADE-ELTROMBOPAG; REG NO/DATE: C(2010)1662 11.03.2010
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
Merck
Boehringer Ingelheim
Medtronic
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.